The latest report by IMARC Group, titled “Australia Molecular Diagnostics Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025–2033,” offers a comprehensive analysis of the Australia molecular diagnostics market growth. The report also includes competitor and regional analysis, along with a breakdown of segments within the industry. The Australia molecular diagnostics market size reached USD 585.20 million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,140.46 million by 2033, exhibiting a growth rate (CAGR) of 6.90% during 2025–2033.• Base Year: 2024
• Forecast Years: 2025–2033
• Historical Years: 2019–2024
• Market Size in 2024: USD 585.20 Million
• Market Forecast in 2033: USD 1,140.46 Million
• Market Growth Rate 2025–2033: 6.90%
Australia Molecular Diagnostics Market Overview
Australia’s molecular diagnostics market is progressing steadily, driven by the rising prevalence of chronic and infectious diseases alongside government-backed healthcare modernization. Laboratories are increasingly adopting advanced platforms such as PCR, next-generation sequencing (NGS), and digital PCR to deliver accurate and rapid diagnostics. National public health initiatives, including bowel and cervical cancer screening programs, are reinforcing demand for early, non-invasive testing. Regional decentralisation efforts are improving access through the rollout of point-of-care infrastructure in remote and underserved areas.
Market players are also shifting toward personalized medicine, integrating genomic testing into routine clinical care to enable more targeted treatment approaches. Strengthened regulatory frameworks and increased investment in laboratory infrastructure—including automation and laboratory information management systems (LIMS)—are enhancing operational efficiency and reducing turnaround times. This transformation is aligning diagnostic services with improved clinical decision-making and cost-efficiency, positioning molecular diagnostics as a foundational component of Australia’s evolving healthcare landscape.
Request For Sample Report:
https://www.imarcgroup.com/australia-molecular-diagnostics-market/requestsample
Australia Molecular Diagnostics Market Growth Drivers:
• Increasing chronic and infectious disease burden fuelling diagnostic volume
• National screening initiatives supporting early molecular testing uptake
• Regulatory support and TGA fast track pathways for advanced assays
• Infrastructure upgrades enabling automation, decentralised workflows
• Personalized medicine trends driving genomic and precision tools integration
Australia Molecular Diagnostics Market Segmentation:
1. By Product Type:
Instruments
Reagents
2. By Technology:
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Microarrays
3. By Application:
Oncology
Infectious Diseases
Genetic Disorders
Others
4. By End User:
Hospitals
Diagnostic Laboratories
Research Institutes
Australia Molecular Diagnostics Market News:
• February 2025: Immunexpress announced the approval of its SeptiCyte® RAPID test by Australia’s Therapeutic Goods Administration (TGA), aiding rapid sepsis diagnosis.
Key Highlights of the Report:
1. Market Performance (2019–2024)
2. Market Outlook (2025–2033)
3. COVID-19 Impact on the Market
4. Porter’s Five Forces Analysis
5. Strategic Recommendations
6. Historical, Current and Future Market Trends
7. Market Drivers and Success Factors
8. SWOT Analysis
9. Structure of the Market